睿知中国医院研究地图
候选清单

正在招募肺癌未注明分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer

ClinicalTrials.gov 上登记的一项肺癌开放试验,由中南大学湘雅二医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方中南大学湘雅二医院Second Xiangya Hospital长沙医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06975384,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically confirmed diagnosis of NSCLC;

    入选标准第 2 条

    Histologically confirmed diagnosis of SCLC;

    入选标准第 10 条

    Pathologically diagnosed as NSCLC;

    入选标准第 18 条

    Pathologically diagnosed as NSCLC;

    入选标准第 26 条

    Pathologically stage confirmed as early stage of IA-IIIA;

    入选标准第 27 条

    Histologically confirmed diagnosis of NSCLC;

    入选标准第 33 条

  3. Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition;

    入选标准第 3 条

    Unresectable locally advanced, metastatic, or recurrent stage Ⅲ-Ⅳ based on AJCC TNM staging 8th edition;

    入选标准第 11 条

    Resectable clinical stage IB-IIIB based on AJCC TNM staging 8th edition;

    入选标准第 19 条

    Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition;

    入选标准第 34 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;

    入选标准第 4 条

    ECOG PS of 0-1;

    入选标准第 12 条

    ECOG PS of 0-1;

    入选标准第 35 条

  5. Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) fusion and/or ROS proto-oncogene 1 (ROS1) fusion-positive;

    排除标准第 1 条

    EGFR-sensitizing mutation and/or ALK fusion and/or ROS1 fusion-positive;

    排除标准第 14 条

  6. Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1);

    入选标准第 6 条

    Presence of at least one measurable lesion according to the RECIST v1.1 ;

    入选标准第 14 条

    At least one measurable lesion can be evaluated according to the RECIST v1.1;

    入选标准第 20 条

    Presence of at least one measurable lesion according to the RECIST v1.1;

    入选标准第 37 条

  7. Presence of other malignant tumors or malignant diseases within 3 years;

    排除标准第 2 条

    Presence of other malignant tumors or malignant diseases within 3 years;

    排除标准第 8 条

    Presence of other malignant tumors or malignant diseases within 3 years;

    排除标准第 15 条

    Presence of other malignant tumors or malignant diseases within 3 years;

    排除标准第 21 条

    Presence of other malignant tumors or malignant diseases within 3 years;

    排除标准第 26 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:既往治疗;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06975384,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥ 18 years old;
  2. Histologically confirmed diagnosis of NSCLC;
  3. Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition;
  4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;
  5. Treatment naïve;
  6. Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1);
  7. Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy;
  8. Informed consent to participate in the study;
  9. Age ≥ 18 years old;
  10. Histologically confirmed diagnosis of SCLC;
  11. Unresectable locally advanced, metastatic, or recurrent stage Ⅲ-Ⅳ based on AJCC TNM staging 8th edition;
  12. ECOG PS of 0-1;
  13. Treatment naïve;
  14. Presence of at least one measurable lesion according to the RECIST v1.1 ;
  15. Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy;
  16. Informed consent to participate in the study;
  17. Age ≥18 years old;
  18. Pathologically diagnosed as NSCLC;
  19. Resectable clinical stage IB-IIIB based on AJCC TNM staging 8th edition;
  20. At least one measurable lesion can be evaluated according to the RECIST v1.1;
  21. Treatment naïve;
  22. Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy as neoadjuvant therapy;
  23. Cardiopulmonary function can withstand surgery;
  24. Informed consent to participate in the study.
  25. Age ≥ 18 years old;
  26. Pathologically diagnosed as NSCLC;
  27. Pathologically stage confirmed as early stage of IA-IIIA;
  28. Available for tumor tissue samples;
  29. Treatment naïve;
  30. Receiving radical surgery;
  31. Informed consent to participate in the study;
  32. Age ≥ 18 years old;
  33. Histologically confirmed diagnosis of NSCLC;
  34. Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition;
  35. ECOG PS of 0-1;
  36. Treatment naive;
  37. Presence of at least one measurable lesion according to the RECIST v1.1;
  38. Receiving targeted therapy or combination with chemotherapy;
  39. Informed consent to participate in the study;
  40. Driver gene-positive.

排除标准:Exclusion Criteria:

  1. Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) fusion and/or ROS proto-oncogene 1 (ROS1) fusion-positive;
  2. Presence of other malignant tumors or malignant diseases within 3 years;
  3. Concurrent acute or chronic psychiatric disorders;
  4. Patients receiving sleep medication;
  5. Prior participation in other clinical drug trials;
  6. Symptomatic brain metastasis;
  7. Inability to complete scale assessments.
  8. Presence of other malignant tumors or malignant diseases within 3 years;
  9. Concurrent acute or chronic psychiatric disorders;
  10. Patients receiving sleep medication;
  11. Prior participation in other clinical drug trials;
  12. Symptomatic brain metastasis;
  13. Inability to complete scale assessments.
  14. EGFR-sensitizing mutation and/or ALK fusion and/or ROS1 fusion-positive;
  15. Presence of other malignant tumors or malignant diseases within 3 years;
  16. Concurrent acute or chronic psychiatric disorders;
  17. Patients receiving sleep medication;
  18. Prior participation in other clinical drug trials;
  19. Symptomatic brain metastasis;
  20. Inability to complete scale assessments.
  21. Presence of other malignant tumors or malignant diseases within 3 years;
  22. Concurrent acute or chronic psychiatric disorders;
  23. Patients receiving sleep medication;
  24. Prior participation in other clinical drug trials;
  25. Inability to complete scale assessments.
  26. Presence of other malignant tumors or malignant diseases within 3 years;
  27. Concurrent acute or chronic psychiatric disorders;
  28. Patients receiving sleep medication;
  29. Prior participation in other clinical drug trials;
  30. Symptomatic brain metastasis;
  31. Inability to complete scale assessments.

引自 ClinicalTrials.gov, NCT06975384, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06975384,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06975384